FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States

Flora Tassone, Ka P. Iong, Tzu Han Tong, Joyce Lo, Louise W. Gane, Elizabeth Berry-Kravis, Danh Nguyen, Lisa Y. Mu, Jennifer Laffin, Don B. Bailey, Randi J Hagerman

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Background: Population screening for FMR1 mutations has been a topic of considerable discussion since the FMR1 gene was identified in 1991. Advances in understanding the molecular basis of fragile X syndrome (FXS) and in genetic testing methods have led to new, less expensive methodology to use for large screening endeavors. A core criterion for newborn screening is an accurate understanding of the public health burden of a disease, considering both disease severity and prevalence rate. This article addresses this need by reporting prevalence rates observed in a pilot newborn screening study for FXS in the US.Methods: Blood spot screening of 14,207 newborns (7,312 males and 6,895 females) was conducted in three birthing hospitals across the United States beginning in November 2008, using a PCR-based approach.Results: The prevalence of gray zone alleles was 1:66 females and 1:112 males, while the prevalence of a premutation was 1:209 females and 1:430 males. Differences in prevalence rates were observed among the various ethnic groups; specifically higher frequency for gray zone alleles in males was observed in the White group compared to the Hispanic and African-American groups. One full mutation male was identified (>200 CGG repeats).Conclusions: The presented pilot study shows that newborn screening in fragile X is technically feasible and provides overall prevalence of the premutation and gray zone alleles in the USA, suggesting that the prevalence of the premutation, particularly in males, is higher than has been previously reported.

Original languageEnglish (US)
Article number100
JournalGenome Medicine
Volume4
Issue number12
DOIs
StatePublished - Dec 21 2012

Fingerprint

Alleles
Newborn Infant
Fragile X Syndrome
Mutation
Genetic Testing
Hispanic Americans
Ethnic Groups
African Americans
Public Health
Polymerase Chain Reaction
Population
Genes

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. / Tassone, Flora; Iong, Ka P.; Tong, Tzu Han; Lo, Joyce; Gane, Louise W.; Berry-Kravis, Elizabeth; Nguyen, Danh; Mu, Lisa Y.; Laffin, Jennifer; Bailey, Don B.; Hagerman, Randi J.

In: Genome Medicine, Vol. 4, No. 12, 100, 21.12.2012.

Research output: Contribution to journalArticle

Tassone, F, Iong, KP, Tong, TH, Lo, J, Gane, LW, Berry-Kravis, E, Nguyen, D, Mu, LY, Laffin, J, Bailey, DB & Hagerman, RJ 2012, 'FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States', Genome Medicine, vol. 4, no. 12, 100. https://doi.org/10.1186/gm401
Tassone, Flora ; Iong, Ka P. ; Tong, Tzu Han ; Lo, Joyce ; Gane, Louise W. ; Berry-Kravis, Elizabeth ; Nguyen, Danh ; Mu, Lisa Y. ; Laffin, Jennifer ; Bailey, Don B. ; Hagerman, Randi J. / FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. In: Genome Medicine. 2012 ; Vol. 4, No. 12.
@article{1e7730096d6f4c5f9b5478ff15cb5687,
title = "FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States",
abstract = "Background: Population screening for FMR1 mutations has been a topic of considerable discussion since the FMR1 gene was identified in 1991. Advances in understanding the molecular basis of fragile X syndrome (FXS) and in genetic testing methods have led to new, less expensive methodology to use for large screening endeavors. A core criterion for newborn screening is an accurate understanding of the public health burden of a disease, considering both disease severity and prevalence rate. This article addresses this need by reporting prevalence rates observed in a pilot newborn screening study for FXS in the US.Methods: Blood spot screening of 14,207 newborns (7,312 males and 6,895 females) was conducted in three birthing hospitals across the United States beginning in November 2008, using a PCR-based approach.Results: The prevalence of gray zone alleles was 1:66 females and 1:112 males, while the prevalence of a premutation was 1:209 females and 1:430 males. Differences in prevalence rates were observed among the various ethnic groups; specifically higher frequency for gray zone alleles in males was observed in the White group compared to the Hispanic and African-American groups. One full mutation male was identified (>200 CGG repeats).Conclusions: The presented pilot study shows that newborn screening in fragile X is technically feasible and provides overall prevalence of the premutation and gray zone alleles in the USA, suggesting that the prevalence of the premutation, particularly in males, is higher than has been previously reported.",
author = "Flora Tassone and Iong, {Ka P.} and Tong, {Tzu Han} and Joyce Lo and Gane, {Louise W.} and Elizabeth Berry-Kravis and Danh Nguyen and Mu, {Lisa Y.} and Jennifer Laffin and Bailey, {Don B.} and Hagerman, {Randi J}",
year = "2012",
month = "12",
day = "21",
doi = "10.1186/gm401",
language = "English (US)",
volume = "4",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central",
number = "12",

}

TY - JOUR

T1 - FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States

AU - Tassone, Flora

AU - Iong, Ka P.

AU - Tong, Tzu Han

AU - Lo, Joyce

AU - Gane, Louise W.

AU - Berry-Kravis, Elizabeth

AU - Nguyen, Danh

AU - Mu, Lisa Y.

AU - Laffin, Jennifer

AU - Bailey, Don B.

AU - Hagerman, Randi J

PY - 2012/12/21

Y1 - 2012/12/21

N2 - Background: Population screening for FMR1 mutations has been a topic of considerable discussion since the FMR1 gene was identified in 1991. Advances in understanding the molecular basis of fragile X syndrome (FXS) and in genetic testing methods have led to new, less expensive methodology to use for large screening endeavors. A core criterion for newborn screening is an accurate understanding of the public health burden of a disease, considering both disease severity and prevalence rate. This article addresses this need by reporting prevalence rates observed in a pilot newborn screening study for FXS in the US.Methods: Blood spot screening of 14,207 newborns (7,312 males and 6,895 females) was conducted in three birthing hospitals across the United States beginning in November 2008, using a PCR-based approach.Results: The prevalence of gray zone alleles was 1:66 females and 1:112 males, while the prevalence of a premutation was 1:209 females and 1:430 males. Differences in prevalence rates were observed among the various ethnic groups; specifically higher frequency for gray zone alleles in males was observed in the White group compared to the Hispanic and African-American groups. One full mutation male was identified (>200 CGG repeats).Conclusions: The presented pilot study shows that newborn screening in fragile X is technically feasible and provides overall prevalence of the premutation and gray zone alleles in the USA, suggesting that the prevalence of the premutation, particularly in males, is higher than has been previously reported.

AB - Background: Population screening for FMR1 mutations has been a topic of considerable discussion since the FMR1 gene was identified in 1991. Advances in understanding the molecular basis of fragile X syndrome (FXS) and in genetic testing methods have led to new, less expensive methodology to use for large screening endeavors. A core criterion for newborn screening is an accurate understanding of the public health burden of a disease, considering both disease severity and prevalence rate. This article addresses this need by reporting prevalence rates observed in a pilot newborn screening study for FXS in the US.Methods: Blood spot screening of 14,207 newborns (7,312 males and 6,895 females) was conducted in three birthing hospitals across the United States beginning in November 2008, using a PCR-based approach.Results: The prevalence of gray zone alleles was 1:66 females and 1:112 males, while the prevalence of a premutation was 1:209 females and 1:430 males. Differences in prevalence rates were observed among the various ethnic groups; specifically higher frequency for gray zone alleles in males was observed in the White group compared to the Hispanic and African-American groups. One full mutation male was identified (>200 CGG repeats).Conclusions: The presented pilot study shows that newborn screening in fragile X is technically feasible and provides overall prevalence of the premutation and gray zone alleles in the USA, suggesting that the prevalence of the premutation, particularly in males, is higher than has been previously reported.

UR - http://www.scopus.com/inward/record.url?scp=84871373139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871373139&partnerID=8YFLogxK

U2 - 10.1186/gm401

DO - 10.1186/gm401

M3 - Article

AN - SCOPUS:84871373139

VL - 4

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 12

M1 - 100

ER -